Philippe Damier

Summary

Affiliation: CHU de Nantes
Country: France

Publications

  1. doi request reprint Drug-induced dyskinesias
    Philippe Damier
    CHU Nantes, CIC 04, Pole NeuroSciences, Nantes, France
    Curr Opin Neurol 22:394-9. 2009
  2. ncbi request reprint [Specificities of the treatment of Parkinson's disease in the elderly]
    Philippe Damier
    CHU de Nantes, Clinique Neurologique, centre d investigation clinique, INSERM UMR 643
    Psychol Neuropsychiatr Vieil 4:S51-9. 2006
  3. ncbi request reprint Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia
    Philippe Damier
    Centre Hospitalier Universitaire de Nantes, centre d investigation clinique, Nantes, France
    Arch Gen Psychiatry 64:170-6. 2007
  4. doi request reprint Levodopa/DDCI and entacapone is the preferred treatment for Parkinson's disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort
    P Damier
    INSERM, CIC04, Nantes, France and CHU Nantes, Clinique Neurologique, Nantes, France
    Eur J Neurol 15:643-8. 2008
  5. ncbi request reprint Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias
    Vincent Paille
    INSERM, UMR 643 and Institut de Transplantation et de Recherche en Transplantation, CHU, Nantes, France
    Mov Disord 22:533-9. 2007
  6. doi request reprint Kinetics of microglial activation and degeneration of dopamine-containing neurons in a rat model of Parkinson disease induced by 6-hydroxydopamine
    Vincent Henry
    Institut National de la Sante et de la Recherche Medicale, UMR 643, CHU de Nantes, Nantes Cedex 01, France
    J Neuropathol Exp Neurol 68:1092-102. 2009
  7. doi request reprint EIF4G1 in familial Parkinson's disease: pathogenic mutations or rare benign variants?
    Suzanne Lesage
    Universite Pierre et Marie Curie PARIS6, Centre de Recherche de l Institut du Cerveau et de la Moelle Epiniere, UMR S975, INSERM, U975, CNRS, UMR 7225, Hopital de la Pitie Salpetriere, Paris, France
    Neurobiol Aging 33:2233.e1-2233.e5. 2012
  8. ncbi request reprint Prospective evaluation of behavioral scales in the behavioral variant of frontotemporal dementia
    Claire Boutoleau-Bretonnière
    Centre Mémoire Recherche et Ressources CMRR, Nantes, France
    Dement Geriatr Cogn Disord 34:75-82. 2012
  9. doi request reprint Non-homogeneous effect of levodopa on inhibitory circuits in Parkinson's disease and dyskinesia
    Laetitia Barbin
    INSERM, CIC 0004, Nantes, France
    Parkinsonism Relat Disord 19:165-70. 2013
  10. ncbi request reprint [Lewy body dementia and Parkinson disease dementia]
    Claire Meyniel
    CHU Nantes, Clinique Neurologique, Nantes 44
    Presse Med 36:1485-90. 2007

Detail Information

Publications32

  1. doi request reprint Drug-induced dyskinesias
    Philippe Damier
    CHU Nantes, CIC 04, Pole NeuroSciences, Nantes, France
    Curr Opin Neurol 22:394-9. 2009
    ..Deep brain stimulation has been shown to be effective to treat severe tardive dyskinesias. This review highlights some recent findings related to levodopa-induced and antipsychotic-induced dyskinesias...
  2. ncbi request reprint [Specificities of the treatment of Parkinson's disease in the elderly]
    Philippe Damier
    CHU de Nantes, Clinique Neurologique, centre d investigation clinique, INSERM UMR 643
    Psychol Neuropsychiatr Vieil 4:S51-9. 2006
    ..Analysis of the different factors involved in the genesis of symptoms in PD (with the putative interest of the use of L-DOPA as a 'diagnostic tool'), and of the comorbidity usually enables cautious and pragmatic solutions to be found...
  3. ncbi request reprint Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia
    Philippe Damier
    Centre Hospitalier Universitaire de Nantes, centre d investigation clinique, Nantes, France
    Arch Gen Psychiatry 64:170-6. 2007
    ..Tardive dyskinesia (TD) is a common and potentially disabling disorder induced by use of antipsychotic drugs for which medical treatment often gives disappointing results...
  4. doi request reprint Levodopa/DDCI and entacapone is the preferred treatment for Parkinson's disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort
    P Damier
    INSERM, CIC04, Nantes, France and CHU Nantes, Clinique Neurologique, Nantes, France
    Eur J Neurol 15:643-8. 2008
    ..This analysis reveals the preference of neurologists for levodopa/DDCI and entacapone over conventional levodopa-modification strategies for the effective treatment of PD motor fluctuations in clinical practice...
  5. ncbi request reprint Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias
    Vincent Paille
    INSERM, UMR 643 and Institut de Transplantation et de Recherche en Transplantation, CHU, Nantes, France
    Mov Disord 22:533-9. 2007
    ..These rats constitute an interesting model of PD, sharing some of the main characteristics of the human disease...
  6. doi request reprint Kinetics of microglial activation and degeneration of dopamine-containing neurons in a rat model of Parkinson disease induced by 6-hydroxydopamine
    Vincent Henry
    Institut National de la Sante et de la Recherche Medicale, UMR 643, CHU de Nantes, Nantes Cedex 01, France
    J Neuropathol Exp Neurol 68:1092-102. 2009
    ..This chronology of events supports the hypothesis that microglial activation is a secondary rather than primary phenomenon in dopaminergic cell degeneration induced by 6-hydroxydopamine...
  7. doi request reprint EIF4G1 in familial Parkinson's disease: pathogenic mutations or rare benign variants?
    Suzanne Lesage
    Universite Pierre et Marie Curie PARIS6, Centre de Recherche de l Institut du Cerveau et de la Moelle Epiniere, UMR S975, INSERM, U975, CNRS, UMR 7225, Hopital de la Pitie Salpetriere, Paris, France
    Neurobiol Aging 33:2233.e1-2233.e5. 2012
    ..G686C) and in a control subject (p.R1197W). These data do not support the pathogenicity of several EIF4G1 variants in PD, at least in the French population...
  8. ncbi request reprint Prospective evaluation of behavioral scales in the behavioral variant of frontotemporal dementia
    Claire Boutoleau-Bretonnière
    Centre Mémoire Recherche et Ressources CMRR, Nantes, France
    Dement Geriatr Cogn Disord 34:75-82. 2012
    ..Yet, few data are available on the long-term relevance of these scales...
  9. doi request reprint Non-homogeneous effect of levodopa on inhibitory circuits in Parkinson's disease and dyskinesia
    Laetitia Barbin
    INSERM, CIC 0004, Nantes, France
    Parkinsonism Relat Disord 19:165-70. 2013
    ..We investigated whether changes in the excitability of inhibitory and excitatory motor circuits could underlie maladaptive mechanisms associated with dyskinesia...
  10. ncbi request reprint [Lewy body dementia and Parkinson disease dementia]
    Claire Meyniel
    CHU Nantes, Clinique Neurologique, Nantes 44
    Presse Med 36:1485-90. 2007
    ..Acetylcholinesterase inhibitors may be useful in both these types of dementia: rivastigmine is approved for treating Parkinson disease dementia and clozapine for reducing hallucinations...
  11. doi request reprint Subthalamic nucleus stimulation reverses spinal motoneuron activity in parkinsonian patients
    Sylvie Raoul
    CHU Nantes, Neurosurgery Department, Hôpital G et R Laënnec, 44093 Nantes, France
    Brain 135:139-47. 2012
    ....
  12. ncbi request reprint Colonic neuropathology is independent of olfactory dysfunction in Parkinson's disease
    Thibaud Lebouvier
    INSERM, U913, Nantes, France
    J Parkinsons Dis 1:389-94. 2011
    ..This suggests that unlike colonic Lewy pathology, OD is unrelated to disease severity. ..
  13. doi request reprint Contrasting changes in cortical activation induced by acute high-frequency stimulation within the globus pallidus in Parkinson's disease
    Pierre Payoux
    INSERM, U 825, CHU Toulouse, Toulouse, France
    J Cereb Blood Flow Metab 29:235-43. 2009
    ....
  14. doi request reprint Value of neuropsychological testing, imaging, and CSF biomarkers for the differential diagnosis and prognosis of clinically ambiguous dementia
    Claire Boutoleau-Bretonnière
    CHU Nantes, Centre de Mémoire et de Ressource et Recherche CM2R, Nantes, France
    J Alzheimers Dis 28:323-36. 2012
    ..Imaging biomarkers mostly contribute to the differential diagnosis between non-AD dementias. Initial neuropsychological testing was poorly contributive in CAD diagnosis...
  15. ncbi request reprint Deep brain stimulation electrodes used for staged lesion within the basal ganglia: experimental studies for parameter validation. Laboratory investigation
    Sylvie Raoul
    Department of Neurosurgery, Centre Hospitalier Universitaire de Nantes, France
    J Neurosurg 107:1027-35. 2007
    ..These leads can be used for creating lesions in the brain. The experimental study reported here was designed to examine the electrical parameters that could be used to create reproducible therapeutic lesions in the brain...
  16. pmc The Val158Met COMT polymorphism is a modifier of the age at onset in Parkinson's disease with a sexual dimorphism
    Stephan Klebe
    centre d investigation clinique, institut du cerveau et de la moelle épinière, Hopital de la Pitie Salpetriere, 47 Boulevard de l Hopital, Paris 75651 Cedex 13, France
    J Neurol Neurosurg Psychiatry 84:666-73. 2013
    ..81). Thus, the Val158Met COMT polymorphism is not associated with PD in the Caucasian population but acts as a modifier of the AAO in PD with a sexual dimorphism: the Val allele is associated with a younger AAO in men with idiopathic PD...
  17. ncbi request reprint Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease
    Vincent Paille
    INSERM, Unite 437, CHU de Nantes, 30 Bd Jean Monnet, 44093 Nantes, France
    Neuroreport 15:561-4. 2004
    ..Moreover, we observed a positive relationship between the percentage dopaminergic cell loss in the SNc and the severity of levodopa-induced AIMs...
  18. doi request reprint Follow-up study of the GIGYF2 gene in French families with Parkinson's disease
    Suzanne Lesage
    INSERM, UMR_S975 Formerly UMR_S679, Hopital de la Salpetriere, Paris, France
    Neurobiol Aging 31:1069-71; discussion 1072-4. 2010
    ..Together, these results do not support a major role of GIGYF2 in PD...
  19. pmc Saccade impairments in patients with fronto-temporal dementia
    C Meyniel
    Service de Neurologie, CHU de Nantes, France
    J Neurol Neurosurg Psychiatry 76:1581-4. 2005
    ..The pattern of saccadic abnormalities has not previously been investigated in patients with FTD...
  20. doi request reprint Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study
    Olivier Rascol
    Laboratoire de Pharmacologie Medicale et Clinique, Pole NeuroSciences, Centre d Investigations Cliniques, Institut National de la Sante et de la Recherche Medicale, Unité 825, University Hospital, Toulouse, France
    Arch Neurol 65:577-83. 2008
    ..To assess the safety and efficacy of tesofensine, a triple monoamine reuptake inhibitor, in patients with advanced Parkinson disease (PD)...
  21. ncbi request reprint [Neuropsychological and scintigraphic aspects of frontotemporal dementia preceding amyotrophic lateral sclerosis]
    M Vercelletto
    Clinique Neurologique, Hôpital R et G Laënnec, Nantes
    Rev Neurol (Paris) 159:529-42. 2003
    ..The links between these two degenerative diseases are discussed...
  22. ncbi request reprint [Handipark: a simple test of the impact of Parkinson's disease on activities of daily living]
    M Ziegler
    Service de Neurologie, Hopital Leopold Bellan, Paris
    Rev Neurol (Paris) 159:767-74. 2003
    ..Further studies are needed to assess its usefulness for the follow-up of patients and assess the therapeutic impact...
  23. ncbi request reprint [Idiopathic acute transverse myelitis: application of new diagnosis criteria to 17 patients]
    C Lanctin
    Pôle de Neurologie médicale et chirurgicale, Hopital Laennec, CHU de Nantes, Saint Herblain, France
    Rev Neurol (Paris) 162:980-9. 2006
    ..Prognosis is not well-known...
  24. ncbi request reprint Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease
    V Mesnage
    centre d investigation clinique, Fédération de Neurologie and Inserm, Paris, France
    Clin Neuropharmacol 27:108-10. 2004
    ..In this exploratory randomized, double-blind, placebo-controlled study, at the dose used, the drugs tested were well tolerated and could not improve parkinsonian motor disability...
  25. ncbi request reprint Parkinson's disease is a neuropsychiatric disorder
    Y Agid
    centre d investigation clinique, INSERM U289, Hopital de la Salpetriere, France
    Adv Neurol 91:365-70. 2003
  26. ncbi request reprint [Cannabis and cannabinoid receptors: from pathophysiology to therapeutic options]
    P Derkinderen
    Service de Neurologie et Centre d investigations cliniques, CHU de Nantes, Hopital Laennec, Nantes
    Rev Neurol (Paris) 160:639-49. 2004
    ..Although cannabis has been used as a medicine for several centuries, the therapeutic properties of cannabis preparations (essentially haschich and marijuana) make them far most popular as a recreational drugs...
  27. ncbi request reprint [Presentation of cerebral toxocariasis with mental confusion in an adult: case report and review of the literature]
    Y Maiga
    Clinique Neurologique, CHU Nantes, Hopital Laennec, Saint Herblain, France
    Bull Soc Pathol Exot 100:101-4. 2007
    ..Finding evidence of specific antibodies in both cerebro spinal fluid and serum is mandatory for the diagnosis. The main clinical features concerning cerebral toxocariasis, diagnostic tools, and therapeutic measures are discussed...
  28. pmc Tourette's syndrome and deep brain stimulation
    J L Houeto
    centre d investigation clinique, Hopital de la Salpetriere, 47 Boulevard de l Hopital, 75013 Paris, France
    J Neurol Neurosurg Psychiatry 76:992-5. 2005
    ..Severe forms of Tourette's syndrome may benefit from stimulation of neuronal circuits within the basal ganglia, thus confirming the role of the dysfunction of limbic striato-pallido-thalamo-cortical systems in this disorder...
  29. pmc Epsilon sarcoglycan mutations and phenotype in French patients with myoclonic syndromes
    S Tezenas du Montcel
    Service de Biostatistique et Information Medicale, Hopital Pitie Salpetriere, AP HP, Paris, France
    J Med Genet 43:394-400. 2006
    ..Myoclonus dystonia syndrome (MDS) is an autosomal dominant movement disorder caused by mutations in the epsilon-sarcoglycan gene (SGCE) on chromosome 7q21...
  30. doi request reprint Is the common LRRK2 G2019S mutation related to dyskinesias in North African Parkinson disease?
    S Lesage
    INSERM UMR 679 former U289, Hopital de la Salpetriere, Paris Cedex 13, France
    Neurology 71:1550-2. 2008
  31. ncbi request reprint Distribution of grey matter atrophy in Huntington's disease patients: a combined ROI-based and voxel-based morphometric study
    G Douaud
    URA CNRS CEA 2210, Service Hospitalier Frederic Joliot, 4, place du General Leclerc, 91 401 Orsay, and Département de Neurologie, CHU Angers, France
    Neuroimage 32:1562-75. 2006
    ..Finally, VBM provided results consistent with previous post mortem results and proved to be a sensitive biomarker capable of correctly managing subcortical distortions throughout HD patients' brains...
  32. pmc Concurrent excitatory and inhibitory effects of high frequency stimulation: an oculomotor study
    B P Bejjani
    centre d investigation clinique, Federation de Neurologie, and INSERM U289, France
    J Neurol Neurosurg Psychiatry 72:517-22. 2002
    ..To describe a reversible neurological condition resembling a crossed midbrain syndrome resulting from high frequency stimulation (HFS) in the midbrain...